Replimune Group, Inc. (NASDAQ:REPL) Sees Significant Drop in Short Interest

Replimune Group, Inc. (NASDAQ:REPL) was the recipient of a large decline in short interest in the month of November. As of November 30th, there was short interest totalling 5,580,000 shares, a decline of 16.5% from the November 15th total of 6,680,000 shares. Based on an average daily volume of 828,800 shares, the short-interest ratio is presently 6.7 days.

Replimune Group Stock Performance

REPL opened at $12.55 on Friday. Replimune Group has a twelve month low of $4.92 and a twelve month high of $17.00. The firm has a market capitalization of $858.67 million, a PE ratio of -4.11 and a beta of 1.26. The company has a current ratio of 10.11, a quick ratio of 10.11 and a debt-to-equity ratio of 0.18. The firm’s 50-day moving average price is $12.19 and its 200 day moving average price is $10.49.

Replimune Group (NASDAQ:REPL) last issued its earnings results on Tuesday, November 12th. The company reported ($0.68) earnings per share for the quarter, topping the consensus estimate of ($0.75) by $0.07. As a group, sell-side analysts expect that Replimune Group will post -2.91 EPS for the current fiscal year.

Insider Activity at Replimune Group

In related news, insider Konstantinos Xynos sold 7,246 shares of the company’s stock in a transaction dated Monday, November 18th. The stock was sold at an average price of $10.78, for a total value of $78,111.88. Following the completion of the transaction, the insider now owns 109,885 shares of the company’s stock, valued at approximately $1,184,560.30. This represents a 6.19 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 8.80% of the company’s stock.

Institutional Trading of Replimune Group

Large investors have recently added to or reduced their stakes in the stock. Nisa Investment Advisors LLC increased its position in Replimune Group by 10,304.2% during the second quarter. Nisa Investment Advisors LLC now owns 4,994 shares of the company’s stock worth $45,000 after purchasing an additional 4,946 shares during the last quarter. Point72 DIFC Ltd acquired a new stake in shares of Replimune Group during the 2nd quarter worth approximately $57,000. Erste Asset Management GmbH purchased a new stake in shares of Replimune Group during the 3rd quarter valued at approximately $133,000. Arizona State Retirement System acquired a new position in Replimune Group in the second quarter valued at approximately $108,000. Finally, China Universal Asset Management Co. Ltd. grew its position in Replimune Group by 82.1% in the third quarter. China Universal Asset Management Co. Ltd. now owns 13,140 shares of the company’s stock worth $144,000 after acquiring an additional 5,926 shares during the period. 92.53% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on the company. Roth Mkm started coverage on Replimune Group in a research note on Tuesday, August 27th. They set a “buy” rating and a $17.00 target price for the company. Roth Capital upgraded shares of Replimune Group to a “strong-buy” rating in a research report on Tuesday, August 27th. BMO Capital Markets lifted their target price on shares of Replimune Group from $14.00 to $18.00 and gave the company an “outperform” rating in a research report on Friday, November 22nd. Jefferies Financial Group upped their price target on shares of Replimune Group from $16.00 to $19.00 and gave the stock a “buy” rating in a research report on Wednesday, December 4th. Finally, JPMorgan Chase & Co. raised their price target on shares of Replimune Group from $14.00 to $17.00 and gave the company an “overweight” rating in a research note on Tuesday, September 24th. Seven analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $17.29.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.